Two distinct dopamine receptor subtypes coexist in the CNS (Kebabian and Calne, 1979; Creese et al., 1983) : D, dopamine receptors mediate the stimulation of adenylate cyclase activity (Hyttel, 1978) , while D, dopamine receptors inhibit the activity of this enzyme (Stoof and Kebabian, 198 1; Onali et al., 1984; Battaglia et al., 1985) . Although many neuroleptics block both dopamine receptor subtypes, previous research has focused on the role of D, dopamine receptors in the mechanism of action of neuroleptic drugs. This was due primarily to the high correlation between the affinities of neuroleptic drugs at the D, dopamine receptor and their clinical dosages as antipsychotic agents (Creese et al., 1976; Seeman et al., 1976) . In addition, selective D, dopamine receptor antagonists such as sulpiride are antipsychotic. Investigations of the D, dopamine receptor were hampered because of the lack of compounds selective for this receptor.
Tardive dyskinesia is a major complication of long-term neuroleptic drug administration used in treating schizophrenia. This disorder is characterized by abnormal movements of the facial muscles, tongue, and extremities (for review, see Baldessarini and Tarsy, 1980) . To provide an animal model of tardive dyskinesia, rodents have been chronically treated with neuroleptic DJD, Receptor Agonist Treatment drugs (Tarsy and Baldessarini, 1974) . The chronic treatment of rodents with neuroleptics does not usually result in the obvious dyskinetic movements of tardive dyskinesia, but does result in an increased sensitivity to the motor stimulatory effects of dopamine agonists, accompanied by an increase in dopamine receptor density. For example, chronic treatment with the D, dopamine receptor-selective antagonist haloperidol results in an increase in D, dopamine receptor density (Burt et al., 1977) . It has been suggested that "pharmacological" denervation of dopamine receptors occurs during chronic antagonist treatment, which results in the supersensitive response to subsequent agonist administration (Creese and Sibley, 198 1) .
In humans and in rodents, the acute administration of neuroleptics results in Parkinsonian or cataleptic extrapyramidal motor side effects, respectively. However, tolerance develops to the extrapyramidal side effects of the classic neuroleptics, such as haloperidol or spiperone, after several weeks of repeated administration (Klett and Caffey, 1972; Ezrin-Waters and Seeman, 1977; Hess et al., 1986a) . Similar to the receptor subtype-selective up-regulation seen following chronic D, dopamine receptor blockade, chronic treatment with the D, dopamine receptor-selective antagonist SCH23390 leads to a selective up-regulation in D, dopamine receptors (Creese and Chen, 1985) . However, rats receiving chronic SCH23390 treatment demonstrate no tolerance to the cataleptogenic effects of this drug (Hess et al., 1986a) . Paradoxially, long-term treatment with antagonists such as fluphenazine or flupentixol, which have equal affinities for the D, and D, dopamine receptors in vitro, has been reported to up-regulate only D, dopamine receptors (Murugaiah etal., 1984; Mackenzieandzigmond, 1985; Boysonetal., 1986) . It is unclear whether tolerance develops to the cataleptogenic effects of the mixed D,/D, dopamine receptor antagonists (Murugaiah et al., 1984) .
Because D, and D, dopamine receptors interact in the modulation of behavior (Arnt and Hyttel, 1985; Breese and Mueller, 1985; Molloy and Waddington, 1985; Hess et al., 1986a) , it is possible that the simultaneous antagonism of D, and D, dopamine receptors by drugs such as flupentixol may modulate or prevent the predicted D, dopamine receptor up-regulation. Alternatively, the paradoxical effects of mixed D,/D, dopamine receptor antagonists may be due to differences in the interactions of these drugs at D, and D, dopamine receptors in vivo. For example, D, dopamine receptors may be situated in a manner that allows a more rapid drug equilibration and prolonged blockade in vivo.
In order to investigate these phenomena further, we have assessed the effects of chronic treatment with a variety of dopamine receptor antagonists on D, and D, dopamine receptor densities and have determined the time course of the cataleptogenic effects of these drugs throughout the chronic treatment regimen. We have also examined the dopamine receptor-blocking properties of the mixed D,/D, dopamine receptor antagonist flupentixol at D, and D, dopamine receptors in vivo using the protein-modifying reagent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Peripherally administered EEDQ has been shown to irreversibly inactivate a number of neurotransmitter receptors, including D, Norman et al., 1987) and D, Hess et al., 1987a) dopamine receptors, S, serotonin (Battaglia et al., 1986) , and ol,-adrenergic receptors (Adler et al., 1985) . EEDQinduced inactivation of these receptors appears to occur at the ligand-recognition site, as EEDQ-induced inactivation can be prevented by prior administration of receptor-selective antagonists (Meller et al., 1985; Battaglia et al., 1986; Hess et al., 1987a) . Meller et al. (1985) have demonstrated that flupentixol administration prior to EEDQ administration will "protect" both D, and D, dopamine receptors from in vivo EEDQ-induced modification. We have examined the time course of the interaction of flupentixol at D, and D, dopamine receptors in vivo by assessing flupentixol protection of D, and D, dopamine receptors from EEDQ-induced inactivation.
Additionally, we have investigated the possible desensitizing effects of the compound L-prolyl-L-leucyl-glycinamide (PLG) on chronic neuroleptic-induced D, dopamine receptor up-regulation. PLG is thought to be a hypothalamic factor that inhibits the release of melanocyte-stimulating hormone (MSH) from the pituitary (Nair et al., 1971) . This tripeptide has been reported to reverse the increased D, dopamine receptor density that occurs after chronic D, dopamine receptor blockade in rats (Chiu et al., 198 1, 1985) . It has been suggested that PLG may be useful in ameliorating the symptoms of tardive dyskinesia in man (Bhargava, 1984) .
Materials and Methods
Chronic drug treatment and behavioral testing. Male Sprague-Dawley rats (180 gm; Simonsen, Gilroy, CA) were maintained in group cages on ad lib food and water and a 12 hr light/dark cycle (6 AM/6PM). Rats were injected daily (s.c.) for 21 d at 10 AM with the following drugs dissolved in saline and a minimal amount of 0.1 N HCl (5.0 ~1 HCl/ml saline): 0.5 mg/kg SCH23390 (n = 12), 1 mg/kg cis-flupentixol (n = 6), 0.2 mg/kg spiperone (n = 12), 0.5 mg/kg SCH23390 plus 0.2 mg'kg spiperone (n = 6). In addition, 6 control rats were injected with the saline vehicle. Rats were tested on days 1, 3, 5, 7, 14, and 21 for a cataleptic response to their administered drug. Also, on day 22, half the group of chrdnic spiperone-treated animals were injected &h 0.5 mg/ kg SCH23390 and half the grouu of chronic SCH23390-treated animals were injected with 0.2 mg/kgspiperone and observed for cataleptic responses. To test for catalepsy, observations were made every 20 min for 2 hr following drug injection. Rats were individually placed in a box (20 x 20 x 30 cm) with a small bar diagonally placed across one comer, 10 cm above the floor. The rat's front paws were placed on the bar and the time taken for the rat to remove both paws was measured, with a cutoff time of 120 set (Sanberg et al., 1984) . Two days following final drug injection, the rats were killed by decapitation and their brains rapidly removed to chilled saline. The striata were dissected, frozen in liquid nitrogen, and stored (l-2 weeks) at -70°C until radioligand binding assay. Those rats receiving an acute antagonist challenge on day 22 were not used in the radioligand binding assays.
To examine the effects of PLG on neuroleptic-induced D, dopamine receptor up-regulation, rats were injected daily (s.c.) with saline (n = 12) or 0.2 mg/kg spiperone (n = 12) for 2 1 d. On the 5 d following this chronic treatment, half the rats receiving saline (n = 6) and spiperone (n = 6) treatment were administered saline (s.c.). The remaining 6 animals from each group were injected daily (s.c.) with 20 mg/kg PLG for 5 d. Two days following final drug injection, rats were killed and striata dissected as described above.
Radioligand binding assays. 3H-SCH23390 saturation analyses to determine D, dopamine receptor density and 3H-spiperone saturation analyses, to determine D, dopamine receptor density were performed in parallel in the striata of each rat. Flupentixol co&petitions for 0.25 nM 3H-SCH23390 or 0.1 nM 3H-spiperone were performed in parallel in control rat striata. Tissue from each animal was homogenized (Tekmar Tissumizer setting 7, 10 set) individually in 40 volumes of ice-cold 50 mM Tris-HCl (pH 7.4 at 37°C). The tissue was centrifuged (35,000 x g, 10 min) and washed once more in the same buffer, followed by a final resuspension in assay buffer consisting of 50 mM Tris-HCl (pH 7.4 at 37°C). 5 mM MESO,. and 0.5 mM EDTA. Incubations for each radioliganh were initiate; by adding tissue (2 mg wet weight tissue/tube) to duplicate tubes containing 3H-antagonists to yield a 2.5 ml final assay volume. All saturation analyses included 6 concentrations of radioligand. Competition and saturation studies of 3H-SCH23390 (0.125-2 nM) were conducted in the presence or absence of 100 nM cis-flupentixol Minutes Post-Injection in order to distinguish the specific from nonspecific binding. All 'Hspiperone assays (0.025-4 nM) were conducted in the presence of 40 nM ketanserin to preclude binding of 3H-spiperone to S, serotonin receptors; nonspecific binding was defined by 1 PM (+)butaclamol. Competition experiments included 2 1 concentrations of flupentixol. Tubes were incubated for 40 min at 37"C, filtered over Whatman GF/C glass-fiber filters that were then washed rapidly with 15 ml (3 x 5 ml) of ice-cold Tris buffer and counted by scintillation spectroscopy at an efficiency of 50%.
-In-vivo ji'upentixol specificity. Male Sprague-Dawley rats (160-l 80 gm; Simonsen) were iniected (i.n.) with EEDO (8 mrr/ka) freshlv dis--.
-II solved in ethr&ol/wate; (1:l voi/vol) or vehicle alone. To determine whether EEDQ had the same EC,, for D, and D, dopamine receptors, a dose-response for EEDQ was performed, in which rats received 1 mg/ kg, 2 mg/kg, or 4 mg/kg EEDQ. For protection experiments testing the specificity of flupentixol in vivo, rats were injected (s.c.) with 0.25, 0.5, 0.75, or 1 mg/kg flupentixol dissolved in saline, or the saline vehicle 40 min before EEDQ (8 mg/kg) injection. Additionally, a second group of rats was injected with 6.5 mg/kg flupentixol or vehicle 20, 40, 66, 80, 100, or 120 min nrior to EEDO (8 mp/ka) iniection. Four hours
after EEDQ treatment, rats were decapitated, the striata removed, frozen rapidly in liquid nitrogen, and stored (-70°C) for 2-4 weeks. Saturation analyses of 'H-antagonist binding were performed in the striata as described above, with the following tissue preparation to facilitate flupentixol washout: Tissue from each animal was individually homogenized in 40 volumes of ice-cold 50 mM Tris-HCl (nH 7.4 at 37°C). The tissue was centrifuged (35,000 x g, 10 min) and &suspended to i0 mg tissue wet weight/ml in this same biffer, followed by a lb min incubation (37°C). The incubation was stopped by the addition of 30 ml ice-cold 50 mM Tris-HCI. Tissue was centrifuged (35,000 x g, 10 min) and washed once more in this buffer, followed by a final resuspension in assay buffer consisting of 50 mM Tris-HCl (PH 7.4 at 37"C), 5mM MgSO,, and 0.5 mM EDTA. The saturation analyses were then comuleted as described above with 3H-SCH23390 a& 3H-spiperone bin&ng performed in parallel on striata from each rat. Data analysis. 'H-Antagonist saturation data were analyzed by the method of Scatchard (1949) . A weighted, nonlinear, least-squares curvefitting program, LIGAND (Munson and Rodbard, 1980) was used in the computer analysis of competition curves. All data were fitted while constraining the nonspecific binding parameter defined by 100 nM cisflupentixol or 1 FM (+)butaclamol.
Data obtained in the catalepsytesting sessions were analyzed using arcsine transform analysis of variance with repeated measures and the Newman-Keuls test.
Materials. 3H-SCH23390 (87 Ci/mmol) and 3H-spiperone (88 Ci/ mmol) were obtained from DuPont-New England Nuclear (Boston, MA). EEDQ was obtained from Aldrich Chemical Co. (Milwaukee, WI), and L-prolyl-L-leucyl-glycinamide from Sigma Chemical Co. (St. Louis, MO). The following drugs were generous gifts from the following sources: butaclamol, Ayerst Laboratories (Montreal, Canada); cis-flupentixol, Figure I . Cataleptic response of rats treated chronically with spiperone (n = 6) or saline (n = 6). Spiperone treatment days 1, 7, and 2 1, and saline treatment day 2 1 are presented. Additionally, data from rats treated with SCH23390 for 2 1 d and then challenged with an acute injection of spiperone on day 22 are presented (n = 6). All drug-treated rats were significantly more cataleptic than saline-treated rats on all testing days (p < 0.001). Catalepsy scores on days 7 and 21 of spiperone treatment and acute spiperone challenge after chronic SCH23390 treatment were significantly lower than scores on spiperone treatment day 10, < 0.00 1). Catalepsy scores from acute spiperone challenge after chronic SCH23390 treatment did not differ significantly from those after day 21 of spiperone treatment. Data represent means + SEM, with a maximum catalepsy score cutoff of 120 sec. Behavioral effects of chronic drug administration The overall catalepsy score, collapsed over each 2 hr session of each daily treatment for rats treated with the D, dopamine receptor-specific antagonist spiperone, decreased over the course of the 21 d treatment (Fig. 1) . A significant reduction in the overall catalepsy score recorded on day 1 of spiperone treatment occurred by day 5 0, < 0.01) and progressively increased over the 21 d period (p < 0.001). However, complete tolerance to the cataleptogenic effects of spiperone was not observed: the overall catalepsy score on testing day 2 1 of rats treated chronically with spiperone was significantly greater 0, < 0.01) than the day 2 1 catalepsy scores ofrats treated chronically with saline.
In contrast to the rats treated with spiperone ( Fig. 1 ) and other classic neuroleptics, in which tolerance to their cataleptogenic effects develops after chronic treatment (Ezrin-Waters and Seeman, 1977) , rats receiving chronic administration of the D, dopamine receptor-selective antagonist SCH23390 for 21 d demonstrated no tolerance to its cataleptogenic action over the 21 d administration (p > 0.05) (Fig. 2) . The cataleptic effects of SCH23390 did diminish over the 2 hr testing session, but the time course of this response did not change from that observed on day 1 over the 21 d treatment period. Cataleptic response of rats treated chronically with SCH23390 (n = 6) on days 1 and 21 of treatment, or saline (n = 6) on day 21 of treatment. SCH23390-treated rats were significantly more cataleptic than saline-treated rats (p < 0.001). The response to SCH23390 treatment did not change over the 21 d treatment regimen. Data represent means ? SEM, with a maximum catalepsy score of 120 sec.
Rats receiving chronic administration of the mixed D,/D, dopamine receptor antagonist flupentixol for 2 1 d demonstrated tolerance to its cataleptogenic action over the 2 1 d administration period, with a significant reduction (p < 0.01) in the overall catalepsy score collapsed over each 2 hr session occurring by day 7 of treatment ( Fig. 3) . This was accompanied by a change in the pattern of catalepsy observed during the 2 hr catalepsy scoring session over the duration of cis-flupentixol treatment. Over the 3 week treatment, in the first 60 min of the scoring session, these animals appeared to become significantly less cataleptic (p < 0.01) after cis-flupentixol administration.
That is, the time between injection and a full cataleptogenic response to cis-flupentixol increased from 20 to 60 min over the 2 1 d administration period. In contrast, the pattern of catalepsy observed Figure 3. Cataleptic response of rats treated chronically with cis-flupentixol (n = 6) on days 1, 5, 7, and 21, or saline (n = 6) on day 21. Flupentixol-treated rats were significantly more cataleptic than salinetreated rats on all days tested (p < 0.001). Catalepsy scores on days 7 and 2 1 were significantly lower (p < 0.0 1) than scores on day 1, owing to a reduction in catalepsy scores at 20,40, and 60 min after flupentixol injection (p < 0.05). Data represent means -I SEM, with a maximum catalepsy score of 120 sec. . Cataleptic response of rats treated chronically with SCH23390 plus spiperone (n = 6) on days 1 and 2 1 of treatment, or saline (n = 6) on day 21 of treatment. SCH23390 plus spiperone-treated rats were significantly more cataleptic than saline-treated rats (p < 0.001). The response to SCH23390 plus spiperone treatment did not change over the 21 d treatment regimen. Data represent means t SEM, with a maximum catalepsy score of 120 sec.
over the 2 hr catalepsy-scoring session did not change for the 2 1 d duration of either SCH23390 or spiperone treatment. Those rats receiving SCH23390 plus spiperone demonstrated no tolerance to the cataleptic effect of this combination of D, and D, dopamine receptor antagonists (Fig. 4) .
When rats were treated with SCH23390 for 21 d and then administered an acute injection of spiperone, tolerance to the cataleptogenic effects of spiperone was observed (Fig. 1) . In fact, the catalepsy scores, collapsed over the 2 hr session following acute challenge with spiperone after chronic 21 d SCH23390 treatment, were not different (p > 0.05) from the scores of chronic spiperone-treated rats on spiperone injection day 2 1. Conversely, rats challenged with an acute injection of SCH23390 . Cataleptic response of rats treated chronically with spiperone for 2 1 d and challenged with an acute injection of either saline (n = 6) or SCH23390 (n = 6) and rats treated with saline for 21 days and challenged with SCH23390. Catalepsy scores for a final SCH23390 injection were significantly greater than for the final saline injection (p < 0.00 1). Catalepsy scores for chronic 2 1 d spiperone treatment and chronic saline treatment with a final SCH23390 challenge did not differ significantly. Data represent means GEM, with a maximum catalepsy score of 120 sec. after 2 1 d spiperone treatment were as profoundly cataleptic as rats that had received the 21 d chronic SCH23390 treatment (Fig. 5) .
Effect of chronic drug treatment on striatal dopamine receptor radioligand binding Consistent with previous reports by this laboratory (Creese and Chen, 1985; Hess et al., 1986a) , chronic treatment with SCH23390 resulted in a highly significant increase (+ 16%) in D, dopamine receptor-specific 3H-SCH23390 binding (p < O.Ol), but no significant change in D, dopamine receptor-specific 3H-spiperone binding was observed (p > 0.05) ( Table 1) . Chronic treatment with the D, dopamine receptor-selective antagonist spiperone resulted in a no significant change in 3H-SCH23390 binding (p > 0.05), while 3H-spiperone binding was significantly increased by 24% (p < 0.001) ( Table 1) . Chronic treatment with SCH23390 plus spiperone resulted in a significant increase in both 3H-SCH23390 (+ 19%) and 3H-spiperone binding (+ 32%) ( Table 1 ). The increase in 3H-spiperone binding in the animals treated with SCH23390 plus spiperone was significantly greater (p < 0.05) than that observed in 3H-spiperone binding in rats treated with spiperone alone. However, the increase observed in 3H-SCH23390 binding in rats treated with SCH23390 plus spiperone did not differ significantly from that in 3H-SCH23390 binding in rats treated with SCH23390 alone. Chronic treatment with the mixed D,/D, dopamine receptor antagonist cis-flupentixol resulted in a significant increase in 3H-spiperone binding only (+24%) (J,J < 0.001) with no change observed in 3H-SCH23390 binding (Table 1 ). The Kds of3H-SCH23390 binding and of 3H-spiperone binding were unchanged by chronic drug treatment in any experimental condition (Table 1) .
Effects of PLG administration following D, dopamine receptor up-regulation The chronic 21 d spiperone treatment resulted in a significant 20% increase in 3H-spiperone binding 0, < 0.0 1). Administration of PLG for 5 d following chronic spiperone treatment did not affect the antagonist-induced D, dopamine receptor up-regulation (Table 2 ). In addition, 5 d PLG administration following 21 d saline treatment did not affect the B,,, of the normosensitive D, dopamine receptor population. In all treatments, the Kd of 3H-spiperone binding was unchanged from control values ( Table 2 ).
Efects of in vivo jlupentixol pretreatment on EEDQ-induced reductions of D, and D, dopamine receptors 3H-SCH23390 and 3H-spiperone binding were markedly reduced by in vivo EEDQ treatment in a dose-dependent manner. In vivo EEDQ-induced reductions in D, and D, dopamine receptors were comparable at all doses of EEDQ; EEDQ has an apparent EC,, of approximately 1.5 mg/kg (i.p.) for both the D, and D, dopamine receptors (Table 3 ). The magnitude of the EEDQ-induced reductions in D, and D, dopamine receptor binding could be reduced by treating rats with flupentixol before EEDQ administration. However, at all doses, flupentixol protected D, dopamine receptor binding to a greater extent than it did D, dopamine receptor binding when flupentixol was injected 40 min before 8 mg/kg EEDQ administration (Table 4 ). In fact, administration of 0.25 mg/kg flupentixol prior to EEDQ treatment protected 66% of D, dopamine receptors, while only 2 1% of D, dopamine receptors were protected by this dose. Admin- istration of 1 mg/kg flupentixol was necessary to achieve a degree of protection of the D, dopamine receptor comparable to that afforded the D, dopamine receptor with 0.25 mg/kg flupentixol. A dose of 0.75 mg/kg flupentixol saturated the D, dopamine receptor, since the degree of protection reached a plateau at this dose, with 86% of D, dopamine receptors protected from irreversible modification by EEDQ. Because the flupentixol-dopamine receptor interaction is a reversible process, with some flupentixol free and some bound at any given instant, it is not surprising that 100% protection was never achieved, especially when using a close to saturating dose of EEDQ, as in these experiments.
To determine whether the differential protection was a timedependent phenomenon based on the accessibility of the drug to each dopamine receptor subtype (i.e., flupentixol had more rapid accessibility to D, dopamine receptors than to D, dopa- (Table 5) . Furthermore, during the second hour of the experiment, protection of D, dopamine receptors declined to approximately 45%, while protection of D, dopamine receptors was -97% during the second hour and had only declined to 82% protection at the 120 min point. In some instances, the Kd of 3H-SCH23390 and 3H-spiperone binding was significantly greater than control values, presumably because of residual flupentixol remaining after the wash procedures, as EEDQ itself does not alter the affinity of 3H-SCH23390 or 3H-spiperone binding (Table 3) .
Discussion
As we have previously reported (Creese and Chen, 1985; Hess et al., i986a) (Arnt and Hyttel, 1985; Molloy and Waddington, 1985; Breese and Mueller, 1985; Hess et al., 1986a) and electrophysiological (Carlson et al., 1987) responses, the lack of an increase in D, dopamine receptor density following chronic flupentixol treatment may be due to a modulatory receptor interaction occurring with concomitant D, and D, dopamine receptor blockade. To The increase in D, dopamine receptors observed after SCH23390 plus spiperone treatment was significantly greater than the increase in D, dopamine receptors after spiperone treatment alone. Thus, chronic blockage of D, dopamine receptors, which alone does not result in a statistically significant D, dopamine receptor up-regulation, potentiated the D, dopamine receptor up-regulation resulting from chronic D, dopamine receptor blockade. Saller and Salama (1986) have recently demonstrated that SCH23390 reduces the in vivo increase in dopamine metabolites elicited by D, dopamine receptor blockade. Thus, it is possible that the potentiation in D, dopamine receptor up-regulation is due to a reduction in dopamine release onto D, receptors caused by the D, dopamine receptor blockade by SCH23390. The reduction in dopamine release would result in an effective increase in D, dopamine receptor blockade by spiperone. Alternatively, another possibility is that the enhanced D, dopamine receptor up-regulation after SCH23390 plus spiperone treatment may be the result of additional direct D, dopamine receptor blockade by SCH23390. Although SCH23390 has minimal D, dopamine receptor affinity in in vitro radioligand binding assays (Hess et al., 1986b) , any small, additional direction D, dopamine receptor blockade caused by SCH23390 in vivo (Stoof and Kebabian, 198 1; on top of the large blockade by spiperone may have been sufficient to induce the greater D, dopamine receptor up-regulation. Clearly, more extensive experimentation is necessary before this question can be answered. The mechanism of action of EEDQ is thought to be due to the creation of highly reactive mixed carbonic anhydrides from carboxyl groups that, in turn, interact with nucleophilic groups such as free a-amino groups (Belleau et al., 1968) . EEDQ also has the capacity to modify enzymes such as serine proteases (Belleau et al., 1968) and adenylate cyclase (Hess et al., 1987a) , in addition to neurotransmitter receptors. In fact, we have demonstrated that in vitro the carboxyl groups of the adenylate cyclase molecule appear to be as sensitive to EEDQ-induced alterations as those carboxyl groups modified at the D, dopamine receptor. Thus, EEDQ-induced modifications seem to be dependent on the availability of carboxyl groups in a given protein. That is, EEDQinduced reductions in the D, and D, dopamine receptor density may be due to nonreceptor-specific carboxyl group modifications rather than to any specific "affinity" EEDQ might have for these receptors.
Since EEDQ induces comparable percentage reductions at D, and D, dopamine receptors, it may be used as a tool to assess the relative interactions of drugs administered in vivo at these receptors. Treatment with flupentixol before the peripheral administration of EEDQ protected both D, and D, dopamine receptors from irreversible blockade by EEDQ, as previously demonstrated (Meller et al., 1985) . However, at all doses of flupentixol tested and at all time points after flupentixol injection, flupentixol protected a greater percentage of D, dopamine receptors than D, dopamine receptors. That is, in vivo, flupentixol demonstrated a preference for the D, dopamine receptor. The lipophilicity of flupentixol, which can result in free ligand depletion, could mask such a small, but functionally significant, difference in the determination of flupentixol affinities in vitro. Conversely, in vivo drug-receptor interactions, assessed from the use of drug treatment followed by EEDQ treatment, would reveal these small differences in affinity provided the drug was administered in a subsaturating dose. The in vivo procedure assesses relative drug interactions at 2 or more receptors simultaneously by measuring fractional occupancy. Thus, small differences in the affinity of a drug for 2 receptors would become obvious because fractional occupancy would never be equal at the different receptors, provided the drug is not at saturating concentrations for the examined receptors. Although this method of drug-induced protection from EEDQ-induced modification in vivo is not suitable for the quantitative determination of drug affinities at receptors, it should provide, with ease, a good reflection of relative drug interactions at specific receptors in vivo. These results are consistent with the results of P. H. Andersen (personal communication), who reports that when using in vivo radioligand binding for a direct quantitative assessment of in vivo receptor affinity, flupentixol in vivo has a higher affinity for D, dopamine receptors than for D, dopamine receptors. In our experiments, flupentixol appears to equilibrate at each dopamine receptor subtype within 40 min after injection, so the behavioral experiments were not confounded by any possible time-dependent differences in the accessibility of the drug to the receptor. Thus, it seems from these results, as well as from the report of P. H. Andersen (personal communication) , that chronic flupentixol treatment does not block a sufficient percentage of D, dopamine receptors to induce up-regulation. These results are noteworthy, as they demonstrate that, just as behavioral drug studies may not always provide an accurate assessment of specific drug-receptor interactions (e.g., the once-accepted hypothesis that apomorphine-induced stereotypies were due solely to D, dopamine receptor activation), extrapolating specific in vivo drug-receptor interactions from in vitro radioligand binding data may be imprecise.
Twenty-one day chronic spiperone treatment, followed by 5 d PLG treatment, had no effect on the D, dopamine receptor density. Previous studies (Bhargava, 1984; Chiu et al., 1985) have reported a PLG-induced reversal in the D, dopamine receptor up-regulation following chronic neuroleptic treatment. Although the experiments described in those reports were fundamentally similar to the protocol described herein, those investigators administered haloperidol rather than spiperone; the difference in chronic drug treatment may account for the striking differences in the putative D, dopamine receptor density-regulatory properties of PGL. PLG may also exert its regulatory effects, preventing neuroleptic-induced D, dopamine receptor up-regulation, if it is administered prior to neuroleptic treatment, as previous reports have suggested (Chiu et al., 198 1, 1985) . Clearly, the prophylactic effects of PLG on dopamine receptor up-regulation require further examination.
As we have previously reported (Hess et al., 1986a) , after chronic treatment with SCH23390 for 21 d, rats demonstrated no tolerance to the cataleptogenic effects of SCH23390. The decrease observed in the cataleptic response to SCH23390 over the 2 hr testing session (Fig. 2) was probably due to rapid metabolism of the drug, rather than a tolerance phenomenon, since it was present on the first administration of the drug. It might be suggested that the prolonged catalepsy response to acute SCH23390 injection following 2 1 d chronic spiperone treatment results from a modulatory effect of the increased D, dopamine receptor density (compare Figs. 2 and 5) . However, rats treated with saline for 21 d also demonstrated a prolonged catalepsy response to acute SCH23390 injection (Fig. 5) . These results suggest that the differences observed in SCH23390-induced catalepsy over the 2 hr testing sessions may reflect the behavioral variability seen when different groups of rats are tested on different days. In contrast to the pattern of catalepsy observed over the course of chronic SCH23390 treatment, rats became progressively tolerant to the cataleptic effects of spiperone; behavioral tolerance to these effects became obvious on treatment day 5, and the rats became progressively more tolerant over the 2 1 d treatment period. Tolerance was not observed to the combination of SCH23390 plus spiperone, with maximal catalepsy scores recorded at all time points on all testing days. Rats treated chronically with flupentixol appeared to become less sensitive to the immediate cataleptic effects of this drug over the course of treatment, but continued to demonstrate profound catalepsy in the second hour after flupentixol administration. Since the EEDQ protection experiments indicated that flupentixol has a greater D, than D, dopamine receptor-blocking activity, it is possible that the behavioral tolerance to flupentixol observed during the first hour after drug administration is a reflection of the development of behavioral tolerance to the D, dopamine receptor antagonism by flupentixol.
The discovery of antagonist drug-induced receptor up-regulation provided an attractive explanation for the behavioral tolerance to chronic antagonist administration (for review, see Creese and Sibley, 198 1) . However, the results described herein demonstrate that this mechanism cannot explain the tolerance or lack of tolerance of the cataleptic response to the chronic administration of dopamine receptor antagonists. It is not yet clear why rats become tolerant to the cataleptogenic effects of D, dopamine receptor antagonists, but do not become tolerant to the D, dopamine receptor antagonist SCH23390. Tolerance to chronic spiperone administration occurs concomitant with a D, dopamine receptor up-regulation but does not occur to chronic SCH23390 administration in spite of a similar concomitant D, dopamine receptor increase. Conversely, in spite of a normal complement of D, dopamine receptors following chronic SCH23390 treatment, rats are just as tolerant to spiperone as they are following chronic spiperone administration. It is possible that in vivo SCH23390 may interact with D, dopamine receptors to induce tolerance to an acute spiperone injection after chronic SCH23390 treatment. However, we have previously demonstrated that treatment with SCH23390 (0.5 mg/kg, s.c.) before peripheral administration of EEDQ protects D, dopamine receptors from irreversible blockade by EEDQ, but that neither D, nor S, serotonin receptors were protected from EEDQinduced modifications by SCH23390 (Hess et al., 1986a) . This indicates that SCH23390 at the dose administered in this study interacts in vivo exclusively with D, dopamine receptors. Thus, behavioral tolerance to an acute injection of spiperone following 21 d chronic SCH23390 treatment is probably not due to any nonspecific effects of SCH23390 at the D, dopamine receptor. It appears then that D, dopamine receptor up-regulation is not necessary for the induction of behavioral tolerance. Although the D, dopamine receptor recognition site may not be up-regulated, alterations in its second-messenger system may have occurred. For example, in a previous study we demonstrated that chronic SCH23390 treatment increased the ability of GTP to activate adenylate cyclase in rat striatal homogenate (Hess et al., 1986a) .
Many studies have demonstrated that D, and D, dopamine receptors are interactive in their modulation of electrophysiological responses, as well as motor behavior. It has recently been suggested that drug-induced changes in the tonic electrical activity of the basal ganglia, particularly the globus pallidus, may reflect drug-induced behavioral effects (Carlson et al., 1987) . That is, agonist-induced increases in pallidal electrical activity seem to correlate approximately with agonist-induced increases in behavioral responses, while the converse is also true. Thus, an increase in D, dopamine receptors induced by chronic SCH23390 treatment may result in an overall increase in the tonic activity of the basal ganglia owing to the enhanced action of endogenous dopamine at the up-regulated D, dopamine receptors. This overall activation imparted by increased D, dopamine receptor activity may be great enough to impart what appears to be behavioral tolerance to a D, dopamine receptor antagonist essentially by "overriding" the D, antagonist signal. These results parallel our earlier findings, where the behavioral effects of the D, receptor agonist LY 17 1555 were potentiated after a selective D, dopamine receptor up-regulation (Hess et al., 1986a) . In fact, we have also previously demonstrated that after D, dopamine receptor up-regulation, rats exhibit an increase in spontaneous locomotor activity (Hess et al., 1986a) . Following D, dopamine receptor up-regulation, however, neither an increase nor decrease in spontaneous activity has been observed (Tarsy and Baldessarini, 1974) . Thus, enhanced D, dopamine receptor stimulation following D, dopamine receptor up-regulation seems to promote an overall increase in activity levels, which may result from the enhanced effectiveness of endogenous dopamine at the up-regulated D, dopamine receptors. Conversely, D, dopamine receptor supersensitivity due to neuroleptic treatment is only apparent when the animal is challenged with a dopamaine receptor agonist. These results support the hypothesis Waddington, 1986 ) that D, dopamine receptor activation may provide a tonic background activation that may be equated with an overall level of arousal. In this model, additional D, dopamine receptor stimulation may be associated with the development of overt stereotyped behavior, which may be regulated by the level of D, dopamine receptor activation, with greater D, dopamine receptor activation yielding more intense agonist-induced D, dopamine receptor-mediated stereotypy.
It has previously been suggested that the symptoms of schizophrenia may be due in part to "overactive" D, dopamine receptors (Memo et al., 1983; Hess et al., 1987b) . Hence, administration of an antipsychotic drug with a potent in vivo D, dopamine receptor antagonist component may be beneficial in certain cases . Such a mixed D,/D, dopamine receptor antagonist would reduce what may be supranormal tonic activity by blocking D, dopamine receptors, while specific "stereotypical" symptoms would be controlled by the D, dopamine receptor antagonist component. While many antipsychotic drugs have equal affinities at D, and D, dopamine receptors in vitro, it is not clear that these drugs are potent antagonists at D, dopamine receptors in vivo, as exemplified by the flupentixol/EEDQ experiments presented herein. Because the 2 dopaminergic systems seem to interact in a synergistic manner Waddington et al., 1986) , it is possible that much lower doses of a drug having equal affinities at D, and D, dopamine receptors in vivo than a D, dopamine receptor-selective antagonist could be used to ameliorate the totality of schizophrenic symptoms, possibly reducing the subsequent incidence of tardive dyskinesia.
Tolerance develops to the extrapyramidal side effects of classic neuroleptics that act primarily at D, dopamine receptors. However, since tolerance to the cataleptogenic effects of SCH23390 was not observed, chronic SCH23390 administration may induce unremitting Parkinsonian extrapyramidal side effects in clinical trials. That tolerance to the cataleptogenicity of SCH23390 plus spiperone treatment was not observed in this study also suggests that a complete D, plus D, dopamine receptor blockade may also produce unremitting Parkinsonian side effects in the clinical setting. However, the doses of the drugs used in this study were rather high and the testing extended only over 2 1 d. It would be useful to test treatments using lower doses of SCH23390 plus spiperone over a longer test period to determine whether the development of tolerance to the extrapyramidal side effects of stimultaneous D, and D, dopamine receptor blockade can occur.
